0000 GMT - Sonic Healthcare may have reiterated its earnings guidance alongside its 1H result today, but Barrenjoey thinks good news may be on the cards from the pathology services provider. Sonic expects FY 2025 Ebitda of A$1.70 billion-A$1.75 billion when currency swings are stripped out. At the midpoint of that range, guidance implies a 52% skew towards 2H, analyst Anshul Baruah says. That is lower than the skew in FY 2019, before Sonic's results got a boost from Covid-19 testing revenues. It suggests Sonic is more likely to achieve the upper end of its Ebitda guidance, Barrenjoey says. Sonic is down 2.3% today. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
February 19, 2025 19:00 ET (00:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。